Increased intracranial pressure in migraine? Neuroimaging study on a cohort of migraineurs

Aim: To investigate the frequency of papilledema and radiological signs of increased intracranial pressure (ICP) in our cohort ofmigraineurs, and investigate the possible clinical predictors.Material and Methods: This was a cross-sectional study in which we have included all the patients with migraine who applied to ourneurology clinic during January 2020 and accepted to involve in the study. The demographic and clinical characteristics includingmigraine subtype (episodic/chronic), headache frequency per month, headache characteristics were evaluated in all the study group.Besides, the presence of chronic fatigue syndrome (CFS) was noted. The fundus examination was performed in all the patients.Previously defined eight findings of increased ICP were evaluated by our radiologist. We have classified the migraineurs into twogroups as migraineurs with clinical suspicion of increased ICP and those without. We have identified the patients with papilledemaand/or positivity of at least one of the neuroimaging signs of increased ICP as migraineurs with suspicion of increased ICP. Theremaining patients were defined as migraineurs without suspicion of increased ICP.Results: Ultimately, 63 migraineurs were included in this study. The median age was 36.8 ± 11.3 and the F/M ratio was 51/12.Papilledema was determined in 11 (17.4%) of the patients and 19 (30.1%) of the migraineurs had at least one of the neuroimagingsigns of increased ICP. Twenty-six (41.3%) of the overall group were evaluated as migraineurs with suspicion of increased ICP and37 of the patients were those without suspicion of increased ICP. The comparisons between these two patient groups revealed thatobesity was more prevalent in the migraineurs with suspicion of increased ICP. Logistic regression analyses revealed obesity (OR:0.090, P = 0.014) and radicular pain (OR: 7,647, P = 0.030) as clinical predictor factors for the patients with suspicion of increased ICP.Conclusion: We determined a high rate of patients with either a positive neuroimaging sign of increased ICP and/or papilledema inour cohort of migraineurs. Our results may suggest obesity and radicular as potential risk factors in the prediction of increased ICP inmigraineurs. The results of this study need to be confirmed in future prospective-studies with the evaluations of the lumbar punctureopening pressures in the patient subgroup with required indication.

PDF

___

1. Yeh WZ, Blizzard L, Taylor BV. What is the actual prevalence of migraine? Brain Behav 2018;8:00950.
2. Cho SJ, Chu MK. Risk factors of chronic daily headache or chronic migraine. Curr Pain Headache Rep 2015;19:465.
3. Mathew NT, Ravishankar K, Sanin LC. Coexistence of migraine and idiopathic intracranial hypertension without papilledema. Neurology 1996;46:1226-30.
4. De Simone R, Ranieri A, Fiorillo C, et al. Is idiopathic intracranial hypertension without papilledema a risk factor for migraine progression? Neurol Sci 2010;31:411-5.
5. De Simone R, Ranieri A, Cardillo G, et al. High prevalence of bilateral transverse sinus stenosis-associated IIHWOP in unresponsive chronic headache sufferers: pathogenetic implications in primary headache progression. Cephalalgia 2011;31:763-5.
6. De Simone R, Ranieri A. The role of intracranial hypertension in the chronification of migraine. Neurol Sci 2015;36:23-8.
7. Favoni V, Pierangeli G, Toni F, et al. Idiopathic Intracranial Hypertension Without Papilledema (IIHWOP) in Chronic Refractory Headache. Front Neurol 2018;9:503.
8. Sengupta S, Eckstein C, Collins T. The Dilemma of Diagnosing Idiopathic Intracranial Hypertension Without Papilledema in Patients With Chronic Migraine JAMA Neurol 2019.
9. Headache Classification Committee of the International Headache S. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33:629-808.
10. Larner AJ. False localising signs. J Neurol Neurosurg Psychiatry 2003;74:415-8.
11. Kosinski M, Bayliss MS, Bjorner JB, et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 2003;12:963-74.
12. Brodsky MC, Vaphiades M. Magnetic resonance imaging in pseudotumor cerebri. Ophthalmology 1998;105:1686-93.
13. Brodsky MC. Flattening of the posterior sclera: hypotony or elevated intracranial pressure? Am J Ophthalmol 2004;138:511.
14. Jinkins JR, Athale S, Xiong L, et al. MR of optic papilla protrusion in patients with high intracranial pressure. AJNR Am J Neuroradiol 1996;17:665-8.
15. Bialer OY, Rueda MP, Bruce BB, et al. Meningoceles in idiopathic intracranial hypertension. AJR Am J Roentgenol 2014;202:608-13.
16. Wang SJ, Silberstein SD, Patterson S, et al. Idiopathic intracranial hypertension without papilledema: a case-control study in a headache center. Neurology 1998;51:245-9.
17. De Simone R, Ranieri A, Montella S, et al. Intracranial pressure in unresponsive chronic migraine. J Neurol 2014;261:1365-73.
18. Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology 2013;81:1159-65.
19. Onder H, Kisbet T. Neuroimaging findings in patients with idiopathic intracranial hypertension and cerebral venous thrombosis, and their association with clinical features. Neurol Res 2020:1-7.
20. Delen F, Peker E, Onay M, et al. The Significance and Reliability of Imaging Findings in Pseudotumor Cerebri. Neuroophthalmology 2019;43:81-90.
21. Bidot S, Saindane AM, Peragallo JH, et al. Brain Imaging in Idiopathic Intracranial Hypertension. J Neuroophthalmol 2015;35:400-11.
22. Hingwala DR, Kesavadas C, Thomas B, et al. Imaging signs in idiopathic intracranial hypertension: Are these signs seen in secondary intracranial hypertension too? Ann Indian Acad Neurol 2013;16:229-33.
23. Kwee RM, Kwee TC. Systematic review and metaanalysis of MRI signs for diagnosis of idiopathic intracranial hypertension. Eur J Radiol 2019;116:106- 15.
24. Peter L, Jacob M, Krolak-Salmon P, et al. Prevalence of papilloedema in patients with sleep apnoea syndrome: a prospective study. J Sleep Res 2007;16:313-8.
25. Del Noce C, Marchi F, Sollini G, et al. Swollen Optic Disc and Sinusitis. Case Rep Ophthalmol 2017;8:421-4.
26. Ball AK, Clarke CE. Idiopathic intracranial hypertension. Lancet Neurol 2006;5:433-42.
27. Wall M. Idiopathic intracranial hypertension. Neurol Clin 1991;9:73-95.
28. Lueck C, McIlwaine G. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev 2005:CD003434.
29. Silberstein S, Diener HC, Lipton R, et al. Epidemiology, risk factors, and treatment of chronic migraine: a focus on topiramate. Headache 2008;48:1087-95.
30. Vieira DS, Masruha MR, Goncalves AL, et al. Idiopathic intracranial hypertension with and without papilloedema in a consecutive series of patients with chronic migraine. Cephalalgia 2008;28:609-13.
31. Santinelli R, Tolone C, Toraldo R, et al. Familial idiopathic intracranial hypertension with spinal and radicular pain. Arch Neurol 1998;55:854-6.
32. Moosa A, Kishore A, Gupta AK, et al. Blindness, ophthalmoplegia and extensive radiculopathy: an unusual clinical syndrome in intracranial sino-venous thrombosis. Neurol India 2004;52:96-8.
33. Obeid T, Awada A, Mousali Y, et al. Extensive radiculopathy: a manifestation of intracranial hypertension. Eur J Neurol 2000;7:549-53.
34. Moosa A, Joy MA, Kumar A. Extensive radiculopathy: another false localising sign in intracranial hypertension. J Neurol Neurosurg Psychiatry. 2004;75:1080-1.